Aegis Still Positive on Catalyst (CPRX) Following Q4 Results; Credit for Firdapse Still Not Given
Tweet Send to a Friend
Aegis Capital reaffrms its Buy rating and $6 price target on Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX) following Q4 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
